Adelaide Medical School
Faculty of Health and Medical Sciences
Dr Alex Staudacher
Postdoctoral Research Scientist, Translational Oncology Laboratory, SA Pathology.
In a bench to bedside effort, researchers in the Translational Oncology Laboratory are applying advances in immunotherapeutic technologies to the treatment of melanoma, ovarian, brain and lung cancers, which affect millions around the world. The two major technologies of interest are antibody therapies using antibody drug conjugates and radioimmunotherapy to target and kill cancer cells, and chimeric antigen receptors (CARs) for re-directing lymphocytes toward cancers.
We are developing pre-clinical and clinical approaches for the treatment of these cancers to aid in diagnosis, therapy monitoring and treatment. Much of our research is collaborative, working in association with the RAH Cancer Clinical Trials Unit and partnering with other laboratories within the Centre for Cancer Biology and SAHMRI as well as national and international collaborations.
Projects in our Laboratory cover the development of novel non-invasive imaging techniques to monitor responses to anti-cancer therapy, using radiolabelled antibodies to target and irradiate tumours from the inside out, identifying novel targets and payloads for antibody drug conjugate therapy and using the bodies own immune system to kill cancer cells through immunotherapy and CAR T-cell therapy.
Research Project 1
Title: Developing novel therapies for imaging and treating cancer
Lung cancer and ovarian cancer are two cancer types with poor treatment outcomes. Antibodies, which specifically target tumour cells, can be harnessed for the detection and eradication of specific tumour cells. We are currently developing two novel antibodies which can be used as predictive markers of tumour response to treatment. We can also harness these antibodies to deliver potent drugs or radiation directly to the tumour site, resulting in greater tumour treatment with less off-target toxicity.
This project will focus on the in vitro and in vivo development of these two antibodies to firstly use them to predict treatment response to chemotherapy using live animal positron emission tomography (PET) and to then use these antibodies as a therapy to treat cancer as antibody drug conjugates or as radioimmunotherapy.
Research Project 2
Title: Non-invasive tracking of CAR T-cells to predict response to therapy
Project description: Chimeric antigen receptor (CAR) T-cells are immune cells which have been reprogrammed to target and kill cancer cells. Currently, there is no real-time, non-invasive method to track these cells when they are re-infused back into the patient to understand how well they target the tumour. For this reason, we are developing new ways to radiolabel CAR T-cells that will allow them to be non-invasively tracked in mouse tumour models through positron emission tomography (PET).
This project will involve the development of novel CAR T-cells for treating solid tumours, in vitro validation, radiolabelling CAR T-cells for in vivo tracking and testing the anti-tumour efficacy of these CAR T-cells in mouse tumour models.
Date Position Institution name 2016 Adjunct Research Associate University of South Australia 2014 Affiliate Lecturer University of Adelaide
Date Institution name Country Title 2007 - 2011 Flinders University Australia PhD 2003 - 2006 Flinders University Australia Bachelor of Science (Hons)
Year Citation 2021 MacGregor, M., Safizadeh Shirazi, H., Chan, K. M., Ostrikov, K., McNicholas, K., Jay, A., . . . Vasilev, K. (2021). Cancer cell detection device for the diagnosis of bladder cancer from urine. Biosensors and Bioelectronics, 171, 12 pages.
DOI Scopus1 Europe PMC1
2020 Staudacher, A. H., Liapis, V., Tieu, W., Wittwer, N. L., & Brown, M. P. (2020). Tumour-associated macrophages process drug and radio-conjugates of the dead tumour cell-targeting APOMAB® antibody. Journal of Controlled Release, 327, 779-787.
DOI Scopus1 WoS1 Europe PMC1
2020 Reid, P., Staudacher, A. H., Marcu, L. G., Olver, I., Moghaddasi, L., Brown, M. P., . . . Bezak, E. (2020). Intrinsic Radiosensitivity Is Not the Determining Factor in Treatment Response Differences between HPV Negative and HPV Positive Head and Neck Cancers.. Cells, 9(8), 14 pages.
2020 Reid, P., Staudacher, A. H., Marcu, L. G., Olver, I., Moghaddasi, L., Brown, M. P., & Bezak, E. (2020). Influence of the human papillomavirus on the radio-responsiveness of cancer stem cells in head and neck cancers. Scientific Reports, 10(1), 8 pages.
DOI Scopus2 WoS2 Europe PMC1
2019 Reid, P., Marcu, L., Olver, I., Moghaddasi, L., Staudacher, A., & Bezak, E. (2019). Diversity of cancer stem cells in head and neck carcinomas: The role of HPV in cancer stem cell heterogeneity, plasticity and treatment response. Radiotherapy and Oncology, 135, 1-12.
DOI Scopus9 WoS10 Europe PMC5
2019 Staudacher, A. H., Li, Y., Liapis, V., Hou, J. J. C., Chin, D., Dolezal, O., . . . Brown, M. P. (2019). APOMAB antibody-drug conjugates targeting dead tumor cells are effective in vivo. Molecular Cancer Therapeutics, 18(2), 335-345.
DOI Scopus4 WoS5 Europe PMC2
2018 Reid, P., Wilson, P., Li, Y., Marcu, L., Staudacher, A., Brown, M., & Bezak, E. (2018). Experimental investigation of radiobiology in head and neck cancer cell lines as a function of HPV status, by MTT assay. Scientific Reports, 8(1), 7 pages.
DOI Scopus7 WoS7 Europe PMC1
2018 Staudacher, A. H., Liapis, V., & Brown, M. P. (2018). Therapeutic targeting of tumor hypoxia and necrosis with antibody α-radioconjugates. Antibody Therapeutics, 1(2), 75-83.
2017 Staudacher, A., & Brown, M. (2017). Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?. British Journal of Cancer, 117(12), 1736-1742.
DOI Scopus74 WoS71 Europe PMC29
2017 Reid, P., Wilson, P., Li, Y., Marcu, L. G., Staudacher, A. H., Brown, M. P., & Bezak, E. (2017). In vitro investigation of head and neck cancer stem cell proportions and their changes following X-ray irradiation as a function of HPV status. PLoS ONE, 12(10), 16 pages.
DOI Scopus12 WoS11 Europe PMC6
2016 Ormsby, R., Staudacher, A., Blyth, B., Bezak, E., & Sykes, P. (2016). Temporal responses to X-radiation exposure in spleen in the pKZ1 mouse recombination assay. Radiation Research, 185(6), 623-629.
DOI Scopus3 WoS3 Europe PMC2
2016 AL Darwish, R., Staudacher, A. H., Li, Y., Brown, M. P., & Bezak, E. (2016). Development of a transmission alpha particle dosimetry technique using A549 cells and a Ra-223 source for targeted alpha therapy. Medical Physics, 43(11), 6145-6153.
DOI Scopus8 WoS7 Europe PMC5
2015 Pishas, K., Adwal, A., Neuhaus, S., Clayer, M., Farshid, G., Staudacher, A., & Callen, D. (2015). XI-006 induces potent p53-independent apoptosis in Ewing sarcoma. Scientific Reports, 5(1), 11465-1-11465-16.
DOI Scopus13 WoS14 Europe PMC12
2015 Pishas, K. I., Adwal, A., Neuhaus, S. J., Clayer, M. T., Farshid, G., Staudacher, A. H., & Callen, D. F. (2015). Erratum: XI-006 induces potent p53-independent apoptosis in Ewing sarcoma (Scientific Reports (2015) 5:11465) doi: 10.1038/srep11465). Scientific Reports, 5(1), 1 page.
DOI Scopus1 WoS1
2015 Al Darwish, R., Staudacher, A., Bezak, E., & Brown, M. (2015). Autoradiography imaging in targeted alpha therapy with Timepix detector. Computational and Mathematical Methods in Medicine, 2015, 612580-1-612580-7.
DOI Scopus9 WoS4 Europe PMC3
2014 Brown, M., & Staudacher, A. (2014). Could bystander killing contribute significantly to the antitumor activity of brentuximab vedotin given with standard first-line chemotherapy for Hodgkin lymphoma?. Immunotherapy, 6(4), 371-375.
DOI Scopus8 WoS6 Europe PMC4
2014 Staudacher, A., Al-ejeh, F., Fraser, C., Darby, J., Roder, D., Ruszkiewicz, A., . . . Brown, M. (2014). The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the la-specific antibody APOMAB®. EJNMMI Research, 4(1), 2-1-2-13.
DOI Scopus17 WoS15 Europe PMC9
2014 Staudacher, A., Bezak, E., Borysenko, A., & Brown, M. (2014). Targeted [alpha]-therapy using 227Th-APOMAB and cross-fire antitumour effects: preliminary in-vivo evaluation. Nuclear Medicine Communications, 35(12), 1284-1290.
DOI Scopus10 WoS10 Europe PMC6
2014 Al-Ejeh, F., Staudacher, A., Smyth, D., Darby, J., Denoyer, D., Tsopelas, C., . . . Brown, M. (2014). Postchemotherapy and tumor-selective targeting with the la-specific DAB4 monoclonal antibody relates to apoptotic cell clearance. Journal of Nuclear Medicine, 55(5), 772-779.
DOI Scopus10 WoS10 Europe PMC4
2014 Penfold, S., Brown, M., Staudacher, A., & Bezak, E. (2014). Monte Carlo simulations of dose distributions with necrotic tumor targeted radioimmunotherapy. Applied Radiation and Isotopes, 90, 40-45.
DOI Scopus5 WoS4 Europe PMC2
2010 Staudacher, A., Blyth, B., Lawrence, M., Ormsby, R., Bezak, E., & Sykes, P. (2010). If bystander effects for apoptosis occur in spleen after low-dose irradiation in vivo then the magnitude of the effect falls within the range of normal homeostatic apoptosis. Radiation Research, 174(6), 727-731.
DOI Scopus12 WoS11 Europe PMC6
2010 Blyth, B. J., Azzam, E. I., Howell, R. W., Ormsby, R. J., Staudacher, A. H., & Sykes, P. J. (2010). An adoptive transfer method to detect low-dose radiation-induced bystander effects in vivo. Radiation Research, 173(2), 125-137.
DOI Scopus13 Europe PMC9
Year Citation 2013 Staudacher, A., & Brown, M. (2013). Synergistic anti-cancer response to chemotherapy and Lu-177-labelled APOMAB((R)) radioimmunotherapy in a preclinical model of lung cancer. Poster session presented at the meeting of EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING. Lyon, FRANCE: SPRINGER.
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2014 - 2017 Co-Supervisor Investigation of Timepix Radiation Detector for Autoradiography and Microdosimetry in Targeted Alpha Therapy Doctor of Philosophy Doctorate Full Time Miss Ruqaya Omar G Al Darwish
Connect With Me